Brooke is an associate editor for The American Journal of Managed Care® (AJMC®). She joined AJMC in 2023, where she produces written content covering multiple disease states.
She has a BA in journalism from Seton Hall University. You can connect with Brooke on LinkedIn.
Varied Access: The Pharmacogenetic Testing Coverage Divide
On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Challenging Perceptions: Exploring Racial, Ethnic Disparities in Psoriatic Arthritis
Although psoriatic arthritis may be more prevalent in White patients, Rebecca Haberman, MD, of NYU Langone Health, emphasizes that the disease affects those across diverse racial and ethnic backgrounds.
Medicaid Unwinding Left Thousands of Pediatric Patients Uninsured
During the unwinding of continuous Medicaid provisions, 8.7% of pediatric patients at community-based health organizations became uninsured, with higher rates among older children, females, and those with chronic medical conditions.
Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care
While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient access to genetic counseling.
Higher Psoriatic Arthritis Disease Burden Found Among Hispanic, Non-White Patients
Hispanic and non-White patients with psoriatic arthritis (PsA) had higher tender joint counts and greater disease severity, highlighting racial and ethnic disparities in PsA disease burden and treatment outcomes.
Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases
First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.
Real-World Study Highlights PARP Inhibitor Challenges in Ovarian Cancer Care
Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for enhanced strategies to optimize postrecurrence treatment.
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Mind the Gap: Patient-Reported PsA Impact Scores, Physician Treatment Decisions Misaligned
While higher patient-reported Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID-12) scores were associated with treatment escalation, physicians primarily relied on clinical assessments when making treatment decisions.
Gynecologic Oncology Practices Evolve With Surgical De-Escalation Trends
Researchers identified a 15-year shift toward surgical de-escalation in gynecologic oncology, marked by fewer surgical interventions, increased adoption of minimally invasive techniques, and a greater focus on fertility preservation and sentinel lymph node procedures.
AI Outperforms Traditional Methods in Predicting Ovarian Cancer Surgery Outcomes
Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients with ovarian cancer, including overall survival, no residual disease, and postoperative complications.